Drug Profile
Research programme: musculoskeletal disorder therapeutics - Five Prime Therapeutics/GlaxoSmithKline
Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics
- Developer Five Prime Therapeutics; GSK
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal disorders
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 04 Nov 2017 No recent reports of development identified for research development in Musculoskeletal-disorders in USA
- 15 Sep 2014 GlaxoSmithKline exercises its option to obtain an exclusive worldwide license to products for the treatment of undisclosed muscle disease target